NCT07125079View on ClinicalTrials.gov

Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

RecruitingOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

May 20, 2026

Study Completion Date

November 20, 2026

Conditions
ARDS (Acute Respiratory Distress Syndrome)
Trial Locations (1)

19104

RECRUITING

Hospital Of the University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Peroxitech Inc
All Listed Sponsors
collaborator

Peroxitech Inc

UNKNOWN

lead

University of Pennsylvania

OTHER

NCT07125079 - Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy. | Biotech Hunter | Biotech Hunter